Merk : Research and development is cheaper in developing countries

Typique d’une mondialisation débridée, les multinationales ne sont qu’imputable qu’aux actionnaires.

Et comme les Chinois coûtent dix fois moins chers que vous et aussi brillants que vous, les jeux sont faits.

Encore une théorie économique à mettre dans les poubelles, on a juste oublié un facteur fondamental : la cupidité et l’avidité fait partie de la nature humaine.

Alors, quand nos brillants économistes vous disent, instruisez vous, je regrette, mais ça ne suffit même plus.

Je demande à certains économistes d’avoir plus de rigueur, car actuellement, vous être totalement dépassé par les évènements, et vous perdez le peu de crédibilité qui vous reste.

Extrait de : Merck follows the money east to China, Robert Cyran, The Globe and Mail, Dec. 06, 2011

Drug research tends to follow spending.

Take Merck’s pledge to invest $1.5-billion (U.S.) in research and development in China over five years.

Emerging economies’ citizens are growing wealthier and living longer, while their governments’ fiscal health is robust.

Oui, tellement robuste, grâce aux règles de l’OMC, un laisser-faire total.

Merck’s step suggests the pharmaceutical industry’s centre of gravity is shifting eastward accordingly.

Growth in developed markets, where drug companies make most of their sales, is slowing to a crawl. The blockbusters of a few years ago are losing patent protection, while strapped governments are clamping down on the prices they are willing to pay for state-funded medical programs. The United States, which accounts for more than a third of total revenue for the sector, saw drug sales increase only 2 per cent last year according to IMS Health.

In some emerging markets, by contrast, drug sales are growing 20 per cent a year or faster. And China’s importance cannot be overstated. It will become the second-biggest drug market in the world by 2020, IMS reckons, as the government implements its $125-billion basic health care plan for all citizens.

While an artist’s atelier doesn’t have to be next to a patron’s palace, it makes sense for pharmaceutical companies to follow the money.

Research and development is cheaper in developing countries, partly because places like India and China are pumping out lots of science and engineering graduates.

Eh oui, M. les économistes à la gomme, examiner le IQ d’un Chinois et d’un Indien, ils sont aussi brillants que nous, sauf, qu’ils coûtent moins chers.

Avec plus de 700 000 ingénieurs qui sortent chaque année des universités chinoises et des budgets de R&D très importants, la Chine possède déjà le hardware d’une championne de l’innovation.

Extrait de : L’innovation «made in China»?

The quality of these researchers and the clinical trials they perform can fall short of the rigorous standards established in developed markets. But both seem to be improving. Also, Merck and its rivals have a better chance of success fighting diseases such as hepatitis B and esophageal cancer – both far more common in China than elsewhere – if they do research and trials on the ground.

Western worries over intellectual property theft haven’t gone away. Merck’s move is modest: a $300-million annual R&D budget in China would only equate to 4 per cent of the $8-billion the company is on track to spend this year. But by investing in the People’s Republic, Merck and competitors like Novartis are establishing bridgeheads in an important market.

They won’t be alone. For drug companies, “Go East” is likely to be a reliable refrain for at least the next decade.

Voici certaines réalités que nos oligarques ne veulent pas diffuser.

1.      New college grads losing ground on wages

2.      U.S.-China Trade killing jobs

3.      Novartis to Cut 2,000 Swiss, U.S. Jobs

4.      America's vanishing science jobs